Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Isturisa (osilodrostat) is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Osilodrostat (Isturisa) achieved a Cushing's disease (CD) control rate of 66.4% (95% CI: 57.9-74.3) in a study involving 97 participants.
• Other drugs demonstrated lower CD control rates, with cabergoline at 35% (95% CI: 27-43%, 141 participants), pasireotide at 44% (95% CI: 25-35%, 522 participants), ketoconazole at 41% (95% CI: 36-46%, 450 participants), and metyrapone at 66% (95% CI: 46-87%, 66 participants).
• Osilodrostat's CD control rate was higher compared to cabergoline, pasireotide, and ketoconazole, and comparable to metyrapone.
• There is no safety information available in the reviewed studies regarding osilodrostat (Isturisa).
• Most frequent adverse events for other drugs: Pasireotide - hyperglycemia; Cabergoline - dizziness and nausea; Metyrapone - dizziness and nausea; Ketoconazole - elevated transaminases.
• There is no population types or subgroups information available in the reviewed studies.